

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

July 2016

Vol. 44, No. 7

CONTENTS

SPECIAL SECTION ON PEDIATRIC DRUG DISPOSITION AND PHARMACOKINETICS

Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. *J. Steven Leeder and Bernd Meibohm* **916**

Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling. *Nitin Mehrotra, Atul Bhattaram, Justin C. Earp, Jeffry Florian, Kevin Krudys, Jee Eun Lee, Joo Yeon Lee, Jiang Liu, Yeruk Mulugeta, Jingyu Yu, Ping Zhao, and Vikram Sinha* **924**

Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. *Nathalie Rioux and Nigel J. Waters* **934**

Effect of Age on The Hepatocellularity Number for Wistar rats. *Sarinj Fattah, Patrick Augustijns, and Pieter Annaert* **944**

Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. *Robin E. Pearce, Roger Gaedigk, Greyson P. Twist, Hongying Dai, Amanda K. Riffel, J. Steven Leeder, and Andrea Gaedigk* **948**

Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny. *Ronald N. Hines, Pippa M. Simpson, and D. Gail McCarver* **959**

The Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxidoreductase 1 (NQO1). *Luc R.A. Rougée, Zoe Riches, Jacob M. Berman, and Abby C. Collier* **967**

Quantification of Flavin-containing Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny. *Yao Chen, Nicole R. Zane, Dhiren R. Thakker, and Michael Zhuo Wang* **975**

Hepatic Cytochrome P450 Activity, Abundance, and Expression Throughout Human Development. *Natalie C. Sadler, Premchendar Nandhikonda, Bobbie-Jo Webb-Robertson, Charles Ansong, Lindsey N. Anderson, Jordan N. Smith, Richard A. Corley, and Aaron T. Wright* **984**

Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics. *Yasmine Elmorsi, Jill Barber, and Amin Rostami-Hodjegan* **992**

Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. *Margaret M. S. Thomson, Ronald N. Hines, Erin G. Schuetz, and Bernd Meibohm* **999**

Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life. *Miriam G. Mooij, Evita van de Steeg, Joost van Rosmalen, Jonathan D. Windster, Barbara A.E. de Koning, Wouter H. J. Vaes, Bianca D. van Groen, Dick Tibboel, Heleen M. Wortelboer, and Saskia N. de Wildt* **1005**

Human Intestinal PEPT1 Transporter Expression and Localization in Preterm and Term Infants. *Miriam G. Mooij, Barbara E. A. de Koning, Dicky J. Lindenbergh-Kortleve, Ytje Simons-Oosterhuis, Bianca D. van Groen, Dick Tibboel, Janneke N. Samsom, and Saskia N. de Wildt* **1014**

Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers. *Carrie A. Vyhldal, Chengpeng Bi, Shui Qing Ye, and J. Steven Leeder* **1020**

Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny. *Nicholas L. Giebel, Jeffrey D. Shadley, D. Gail McCarver, Kenneth Dorko, Roberto Gramignoli, Stephen C. Strom, Ke Yan, Pippa M. Simpson, and Ronald N. Hines* **1027**

Age-Specific Regulation of Drug-Processing Genes in Mouse Liver by Ligands of Xenobiotic-Sensing Transcription Factors. *Cindy Yanfei Li, Helen J. Renaud, Curtis D. Klaassen, and Julia Yue Cui* **1038**

Continued on next page

☐ Kidney versus Liver Specification of SLC and ABC Drug Transporters, Tight Junction Molecules, and Biomarkers. *Gleb Martovetsky, Kevin T. Bush, and Sanjay K. Nigam* **1050**

☐ Correlation between Conjugated Bisphenol A Concentrations and Efflux Transporter Expression in Human Fetal Livers. *Jamie E. Moscovitz, Muna S. Nahar, Stuart L. Shalat, Angela L. Slitt, Dana C. Dolinoy, and Lauren M. Aleksunes* **1061**

☐ Decreased Pregnane X Receptor Expression in Children with Active Crohn's Disease. *Valentina Shakhmovich, Carrie Vyhldal, Craig Friesen, Amber Hildreth, Vivekanand Singh, James Daniel, Gregory L. Kearns, and J. Steven Leeder* **1066**

☐ Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. *Jean C. Dinh, Robin E. Pearce, Leon Van Haandel, Andrea Gaedigk, and J. Steven Leeder* **1070**

☐ Examining Small Intestinal Transit Time as a Function of Age: Is There Evidence to Support Age-Dependent Differences among Children?. *Anil R. Maharaj and Andrea N. Edginton* **1080**

How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach. *Trevor N. Johnson, Masoud Jamei, and Karen Rowland-Yeo* **1090**

☐ Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio. *Farzaneh Salem, Khaled Abduljalil, Yoshiteru Kamiyama, and Amin Rostami-Hodjegan* **1099**

☐ Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows—A Physiologically Based Pharmacokinetic Approach. *Muhammad Fawad Rasool, Feras Khalil, and Stephanie Läer* **1103**

Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. *Jessica K. Roberts, Anna V. Birg, Tong Lin, Vinay M. Daryani, John C. Panetta, Alberto Broniscer, Giles W. Robinson, Amar J. Gajjar, and Clinton F. Stewart* **1116**

ARTICLES

☐ Cardiotoxic Pill Reduces Myocardial Ischemia-Reperfusion Injury via Increasing EET Concentrations in Rats. *Meijuan Xu, Haiping Hao, Lifeng Jiang, Yidan Wei, Fang Zhou, Jianguo Sun, Jingwei Zhang, Hui Ji, Guangji Wang, Wenzheng Ju, and Ping Li* **878**

Zomepirac Acyl Glucuronide Is Responsible for Zomepirac-Induced Acute Kidney Injury in Mice. *Atsushi Iwamura, Katsuhito Watanabe, Sho Akai, Tsubasa Nishinosono, Koichi Tsuneyama, Shingo Oda, Toshiyuki Kume, and Tsuyoshi Yokoi* **888**

New Insights in Tissue Distribution, Metabolism, and Excretion of [³H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. *Markus Walles, Bettina Rudolph, Thierry Wolf, Julien Bourgailh, Martina Suetterlin, Thomas Moenius, Gisela Peraus, Olivier Heudi, Walid Elbast, Christian Lanshoeft, and Sanela Bilic* . . . **897**

Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers. *Shotaro Uehara, Yasuhiro Uno, Takashi Inoue, Mirai Kawano, Makiko Shimizu, Akiko Toda, Masahiro Utoh, Erika Sasaki, and Hiroshi Yamazaki* **911**

Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo. *Qi J. Yang, Jianghong Fan, Shu Chen, Lutan Liu, Huadong Sun, and K. Sandy Pang* **1123**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Exposure response and dose-response of adalimumab in pediatric patients with CD during the maintenance phase. See the article by Mehrotra et al. (dx.doi.org/10.1124/dmd.116.069559).